These findings indicate that IMM2902 not only exerts direct anti-tumor effects by targeting tumor cells but also reshapes the TME to enhance immune cell infiltration and function, offering a novel therapeutic strategy for HER2+ breast cancer, especially for patients resistant to trastuzumab. This evidence concerns the gene ERBB2 and breast carcinoma.